Traditional clinicopathological parameters such as imaging parameters, serum alpha fetoprotein level and tumor stage only offer limited efficacy for prognosis prediction and fail to effectively guide the individualized therapeutics for HCC2. This evidence concerns the gene AFP and neoplasm.